The multi-year partnership will boost the production of Radium-224, strengthening the supply of critical isotopes for Targeted Alpha Therapies (TATs).
ST. LOUIS, Mo (Oct. 17,2024)– TAG1 Inc., a premier supplier of clinical quantities of medical isotopes, has entered into a unique multi-year partnership with NRG PALLAS, a global authority in nuclear solutions, to secure a critical supply of Radium-224 for the production of Lead-212 (Pb-212) isotope. This agreement aims to strengthen the supply chain for innovative radiopharmaceutical cancer treatments, including Targeted Alpha Therapies (TATs), which hold great promise for treating tumors that have been traditionally difficult to target.
Under the agreement, NRG PALLAS and TAG1, Inc. will collaborate to produce critical isotopes including Radium-224 and its daughter isotope, Lead-212. Lead-212 is increasingly recognized for its role in TATs, offering precision treatments by delivering potent alpha particles directly to cancerous cells while sparing healthy tissue. This innovative collaboration will bolster the availability of critical isotopes, supporting the development and delivery of life-saving therapies to cancer patients.
“We are thrilled to announce our partnership with NRG PALLAS. This organization continues to be a leader in the production of key isotopes, and this relationship has the potential to be a game-changer in Targeted Alpha Therapies (TATs).”, commented Sumit Verma, CEO of TAG1, Inc. “This agreement strengthens both company’s ability to make a measurable difference in patient lives and will further position TAG1 as a premier supplier for the radiopharma industry. We look forward to contributing towards innovative cancer therapies that can improve patient outcomes globally.”
Vinod Ramnandanlal, Commercial Director of NRG PALLAS added, “Together, we are fortifying the future accessibility and scalability of vital medical isotopes required to develop life-saving therapies. This partnership secures a reliable supply chain for these critical isotopes, supporting advancements in clinical applications and commercial efforts, and helping to shape the future of cancer care.”
This innovative partnership exemplifies how collaborative efforts between industry leaders can drive the next generation of nuclear medicine, ensuring that the supply chain of rare isotopes can meet the growing demand for personalized and targeted cancer treatments. The continued production of critical materials like Lead-212, backed by NRG PALLAS’ advanced facilities and TAG1’s cutting-edge processing capabilities, will significantly impact the development and delivery of breakthrough radiopharmaceuticals to patients worldwide.
About TAG1 Inc.
TAG1 Inc. is a leading supplier of medical isotopes, specializing in the production of Lead-212 (Pb-212) for use in Targeted Alpha Therapies (TATs). The TAG1 Generator is a proprietary and innovative generator designed to unlock the supply of Pb-212 for pre-clinical and clinical trials of targeted alpha therapies utilizing this vital radioisotope. With a mission to improve cancer treatment through innovative nuclear medicine, TAG1 Inc. is dedicated to advancing the radiopharmaceutical supply chain and supporting the development of groundbreaking therapies.
About NRG PALLAS
NRG PALLAS is a world leader in nuclear solutions, specializing in the production of medical isotopes and the development of advanced nuclear technologies.
With the High Flux Reactor, NRG PALLAS produces medical isotopes for diagnosis and therapeutic treatment of life-threatening diseases. Every day, 30,000 patients rely on medical isotopes from Petten. To ensure future security of the supply, preparations are made for the construction of the PALLAS reactor to replace the HFR.
For media inquiries, please contact:
Sumit Verma
CEO
TAG1, Inc.
info@orchestralifesciences.com
Bieke Oskam
Senior Communications Advisor
NRG PALLAS
oskam@nrg.eu
